LY450139: tolerability and biomarker assessment in subjects with mild to moderate Alzheimer's disease.

Trial Profile

LY450139: tolerability and biomarker assessment in subjects with mild to moderate Alzheimer's disease.

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Jan 2010

At a glance

  • Drugs Semagacestat (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Biomarker
  • Sponsors Eli Lilly
  • Most Recent Events

    • 16 Jan 2007 Status change
    • 16 Aug 2006 Status change
    • 15 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top